Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

for questions. Please be advised that this call is being recorded and a replay will be available. You can find information on the replay and further information related to today's announcements on the Sparrow Therapeutics website at www.sparrotherapeutics.com. At this time, I would like to turn the call over to Shai Biran, Senior Director, Investor Relations. Mr. Biran, please go ahead. Thank you, Operator, and thank you all for participating in today's conference call. This afternoon, Sparrow Therapeutics released financial results and provided a business update for the second quarter of 2024. The press release is available on the investor page of the Sparrow Therapeutics website. Before we begin, I would like to remind you that some of the information presented on this conference call contains forward-looking statements under the securities laws. These forward-looking statements involve substantial risks and uncertainties that could cause our actual clinical program, future results, progress, timing, performances, or achievements to differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties associated with our business and factors that could cause or contribute to such differences are described in detail in sterile therapeutic filings with the SEC, including in the risk factor section of its earnings report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC today. We also ask that you reference the cautionary statement or forward-looking statement included with the slide presentation accompanying this conference call. Participating in today's call are Saab Shukla, Chief Executive Officer, and Esther Rajavelu, Chief Financial Officer and Chief Business Officer. Seth Shukla will begin the disc...